Ruptured hepatic metastases of cutaneous melanoma during treatment with vemurafenib: an autopsy case report

BMC Clinical Pathology
Takuto NosakaYasunari Nakamoto

Abstract

The spontaneous rupture of hepatic metastases is rare compared to that of primary hepatic tumors. In addition, vemurafenib, a selective inhibitor of the mutant BRAF protein or gene product, has been reported to be extremely effective in patients with metastatic melanoma who harbor a BRAF V600E mutation. A 44-year-old female had previously undergone surgery for resection of a malignant melanoma in the lower right leg. Four years later, hepatic metastases became apparent, and transcatheter arterial embolization (TAE) was performed. Then she underwent treatment with vemurafenib. The size of the hepatic metastases markedly decreased. Two months later, they enlarged rapidly and ruptured, requiring emergency TAE. However, the patient developed hemorrhagic shock and died of renewed intra-abdominal bleeding on the 26th postoperative day. This is a rare case of ruptured hepatic metastases of malignant melanoma during treatment with vemurafenib. Postmortem examination and immunohistochemical analysis indicated reactivation of the mitogen-activated protein kinase pathway in the metastatic tumor, suggesting secondary resistance to vemurafenib as the possible underlying mechanism.

References

Sep 1, 1976·The British Journal of Surgery·R MokkaT K Larmi
Mar 1, 1978·American Journal of Surgery·J H Foster
Nov 1, 1991·Postgraduate Medical Journal·M Welch
Jul 1, 1991·The Japanese Journal of Surgery·T DouseiY Kawashima
Nov 1, 1985·Archives of Surgery·W H WagnerA J Donovan
Oct 21, 1972·British Medical Journal·G B Ong, J L Taw
Dec 22, 2000·Clinical Imaging·R MurakamiT Ichikawa
Jun 18, 2002·Nature·Helen DaviesP Andrew Futreal
Oct 1, 1964·Cancer·T DASGUPTA, R BRASFIELD
Feb 12, 2005·Internal Medicine·Maiko SakaiRyuzo Ueda
Jun 30, 2010·Japanese Journal of Radiology·Ho Jong ChunHironobu Nakamura
Sep 8, 2010·The New England Journal of Medicine·Keith T FlahertyPaul B Chapman
Jun 7, 2011·The New England Journal of Medicine·Paul B ChapmanUNKNOWN BRIM-3 Study Group
May 8, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christopher J AnkerKenneth F Grossmann
Nov 23, 2013·Cancer Discovery·Eliezer M Van AllenUNKNOWN Dermatologic Cooperative Oncology Group of Germany (DeCOG)

❮ Previous
Next ❯

Citations

Oct 28, 2015·Journal of Surgical Oncology·Devin C FlahertyMark B Faries
Apr 30, 2016·Texas Heart Institute Journal·Herbert L Fred
Dec 12, 2019·Hepatobiliary & Pancreatic Diseases International : HBPD INT·Panagiotis LainasIbrahim Dagher

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Related Papers

The New England Journal of Medicine
Jason P Lott
The New England Journal of Medicine
Stéphane DalleLuc Thomas
The New England Journal of Medicine
Hiroyuki Morita, Ryozo Nagai
Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
Toru TakamatsuShigeki Yamada
© 2021 Meta ULC. All rights reserved